Argen-X (ARGX.BR) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Belgium · ISIN NL0010832176
Argen-X financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.25 bn USD | 4.15 bn USD |
| Gross profit | 1.96 bn USD | 3.70 bn USD |
| Operating income | -21.65 m USD | 1.03 bn USD |
| EBIT | -17.84 m USD | 1.03 bn USD |
| Net income | 833.04 m USD | 1.34 bn USD |
| Diluted EPS – continuing operations | 12.78 USD | 20.37 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
More stocks
- NXP Semiconductors (NXPI)
- Societe Generale SA (GLE.PA)
- AP Moeller - Maersk A/S (MAERSK B.CO)
- Truist Financial (TFC)
- AP Moeller-Maersk AS (AMKBY)
- Diamondback Energy (FANG)
- Dominion Energy (D)
- Baker Hughes (BKR)
- Devon Energy (DVN)
- Loblaw Companies Ltd (L.TO)
- Comfort Systems USA (FIX)
- Vale SA (VALE3.SA)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.